Commercially available and scalable growth factor and cytokines agonists and antagonists development

Identifying key opinion leaders from target research sectors with managing prototype evaluations

Market development with selecting key clients from global pharmaceutical companies

Managing global supply chain

Prioritise types of growth factors for market-in

AdobeStock_198333071.jpeg

Business Information:

Name of the company:

PeptiGrowth Inc.

Year of establishment:

2021

Location of the headquarters:

Tokyo, Japan

Other key location(s):

Spinout from:

PeptiDream, Mitsubishi Corporation

Year of establishment:

2021

Growth factors are a class of proteins that are widely present in humans and other animals. In addition to playing an important role in cell growth and proliferation, it is crucially involved in induction of differentiation of stem cells (iPS cells, ES cells, etc.) into nerve, blood, and other types of cells. Currently, growth factors are mainly extracted from animal serum or produced by gene recombination technology, however, their production presents a number of challenges to the pharmaceutical industry, including safety risks due to contamination with impurities, variation in quality among production lots, and high production costs.

PeptiGrowth will utilize PeptiDream's proprietary drug discovery platform system, PDPS (Peptide Discovery Platform System), to identify alternative peptides that perform the equivalent function as growth factors, and develop a new chemical synthesis method that does not use animal serum or gene recombination technology. In addition, by establishing a commercial manufacturing process and system, PeptiGrowth will achieve high purity, less variation among production lots in terms of specification and quality, with lower costs. Dozens of growth factors have been identified to date, and in order to realize a completely xeno-free culture medium, multiple growth factors need to be replaced with chemically synthesized alternative compounds. This is a world-first in terms of the comprehensive development of chemically synthesized, peptide alternatives to multiple growth factors. PeptiGrowth believes such an initiative to realize the peptide alternatives to multiple growth factors is essential for further advancement of cell therapy and regenerative medicines in the industry.

Company website:

PeptiGrowth

Technology validation:

ビジネスミーティング

Technology readiness level (TRL)

8

CEO message:

Value if IP (patents)

creative innovation success.jpg

Current business stage:

Commercial development, non-GMP grade

Next investment required:

Target exit style:

Clinical study level (if relevant):

Jiro Sugimoto

Technical literatures:
Biospire's roles:
    Global business development and marketing support.